Diane Darsin-Bettinger

Learn More
Treatment with retinoic acid (RA) is effective to restore radioactive iodine uptake in metastases of a small fraction of thyroid cancer patients. In order to find predictive markers of response, we took advantage of two thyroid cancer cell lines, FTC133 and FTC238, with low RA-receptor (RAR)β expression but differing in their response to RA. We report that(More)
PURPOSE Retinoic acid (RA) treatment has been used for redifferentiation of metastatic thyroid cancer with loss of radioiodine uptake. The aim of this study was to improve the understanding of RA resistance and investigate the role of bexarotene in thyroid cancer cells. EXPERIMENTAL DESIGN A model of thyroid cancer cell lines with differential response to(More)
Dear Sir, We read with interest the recently published article with the new EANM paediatric dosage card [1]. However, we were surprised by the 18F-FDG activity in PET. As a matter of fact, “F-18 FDG (2D)” was changed to “FDG-PET torso” and “F-18 FDG (3D)” to “FDG-PET brain” with respectively the same parameters, but the 2D and 3D modes referred to a(More)
Abbreviations : ATRA, all-trans-retinoic acid ; DTC, differentiated thyroid cancer ; FTC, follicular thyroid carcinoma ; NIS, Na/I symporter ; NF-kappaB, nuclear factor kappaB; RA, retinoic acid ; RAR, retinoic acid receptor ; RARE, retinoic acid response element ; RXR, retinoid X receptor ; TG, thyroglobuline ; TPO, thyroid peroxydase ; TSHR, thyroid(More)
  • 1